Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Share Talk Bulletin Board Heroes, Monday 29th March 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Tiziana Life Sciences plc (TILS.L) Chairman of Tiziana to give interview on Bloomberg
Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give an interview on Bloomberg Television US at 1:20 PM ET Today
Share Talk Bulletin Board Heroes, Tuesday 2nd March 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Share Talk Bulletin Board Heroes, Friday 26th February 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Tiziana Life Sci PLC (TILS.L) Tiziana Interview to Air on Bloomberg TV
Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) Tiziana at BIO CEO & Investor Digital Conference
Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
Tiziana Life Sci PLC (TILS.L) Appointment of Dr Thomas Adams, Ph.D. as an executive director
NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana Life Sci PLC (TILS.L) CEO exclusive interview to discuss COVID-19 Trial
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
Share Talk Bulletin Board Heroes, Tuesday 2nd February 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Tiziana Life Sci PLC (TILS.L) Positive Data: Nasal Administration of Foralumab
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.Nasdaq.L) Updated corporate presentation
New York/London, 26 January 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and